Resource Library
Boosting cell culture yields with intensified fed batch processing
With its core innovation of N-1 perfusion, Intensified Fed-Batch (IFB) cell culture technology represents a significant advancement in biopharmaceutical manufacturing, addressing the limitations of traditional fed-batch (TFB) processes. This whitepaper discusses how our advanced IFB platform, S-Tensify™, enables faster and more efficient development cycles while maintaining high quality across various therapeutic modalities. Read more
The new gold standard in cell culture technology
Intensified fed-batch (IFB) culture, an innovative approach that addresses the limitations of traditional fed-batch (TFB) culture, can improve the quality and titers for a cell culture process by incorporating perfusion processes into the workflow. Typically, this perfusion allows a process to achieve a higher density of viable cells during the N-1 step, prior to introduction to the production bioreactor, in turn enabling a higher inoculation cell density in the main culture.
Optimizing for high cell density
In this whitepaper, we detail how S-Tensify™, a groundbreaking IFB platform process developed by Samsung Biologics, takes this concept a step further to achieve optimal production efficiency. Using S-Tensify™, Samsung Biologics tailors cell culture processes to maximize productivity for different cell lines used in biopharmaceutical manufacturing, thereby supporting more efficient, streamlined biopharmaceutical production.
With its core innovation of N-1 perfusion, Intensified Fed-Batch (IFB) cell culture technology represents a significant advancement in biopharmaceutical manufacturing, addressing the limitations of traditional fed-batch (TFB) processes. This whitepaper discusses how our advanced IFB platform, S-Tensify™, enables faster and more efficient development cycles while maintaining high quality across various therapeutic modalities. Read more
The new gold standard in cell culture technology
Intensified fed-batch (IFB) culture, an innovative approach that addresses the limitations of traditional fed-batch (TFB) culture, can improve the quality and titers for a cell culture process by incorporating perfusion processes into the workflow. Typically, this perfusion allows a process to achieve a higher density of viable cells during the N-1 step, prior to introduction to the production bioreactor, in turn enabling a higher inoculation cell density in the main culture.
Optimizing for high cell density
In this whitepaper, we detail how S-Tensify™, a groundbreaking IFB platform process developed by Samsung Biologics, takes this concept a step further to achieve optimal production efficiency. Using S-Tensify™, Samsung Biologics tailors cell culture processes to maximize productivity for different cell lines used in biopharmaceutical manufacturing, thereby supporting more efficient, streamlined biopharmaceutical production.